Skip to main content
Erschienen in: Journal of Artificial Organs 1/2014

01.03.2014 | Original Article

Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients

verfasst von: Hirotaka Nakamoto, Chieko Hamada, Tetsutaro Shimaoka, Yoshimi Sekiguchi, Hiroaki Io, Kayo Kaneko, Satoshi Horikoshi, Yasuhiko Tomino

Erschienen in: Journal of Artificial Organs | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Characteristics of pathological alterations in long-term peritoneal dialysis (PD) are thickening of submesothelial compact (SMC) zone, small-vessel vasculopathy, and loss of mesothelial cells. Bioincompatible PD fluid plays crucial roles in peritoneal injury. Encapsulating peritoneal sclerosis (EPS), a rare and serious complication, occurred in patients on long-term PD or frequent peritonitis episodes, and ~50 % of EPS developed after PD cessation. We hypothesized that PD-related peritoneal injury factors induced by bioincompatible PD fluid accumulated in the peritoneum and might induce EPS. We therefore examined the accumulation of advanced glycation end products (AGE) and beta 2-microglobulin (β2M) in peritoneum and evaluated the relationship between their accumulation, clinical parameters, and outcome after PD cessation. Forty-five parietal peritoneal specimens were obtained from 28 PD patients, 14 uremic patients, and three patients with normal kidney function. The peritoneal equilibration test was used for peritoneal function. AGE- and β2M-expressing areas were found in vascular walls, perivascular areas, and the deep layer of the SMC in short-term PD patients and extended over the entire SMC in long-term patients. Peritonitis and prolonged PD treatment aggravated peritoneal thickening and the proportion of AGE-expressing areas. The proportion of β2M-expressing areas was increased in long-term PD patients. Thickening of the SMC and the proportions of AGE- and β2M-expressing areas were not related to ascites or EPS after PD withdrawal. It appears that the increased proportion of AGE and β2M deposition induced by long-term exposure of PD fluid may be a marker of peritoneal injury.
Literatur
1.
Zurück zum Zitat Di Paolo N, Sacchi G, De Mia M, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron. 1986;44:204–11.PubMedCrossRef Di Paolo N, Sacchi G, De Mia M, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron. 1986;44:204–11.PubMedCrossRef
2.
Zurück zum Zitat Gotloib L, Shostak A. Ultrastructural morphology of the peritoneum: new findings and speculations on transfer of solutes and water during peritoneal dialysis. Perit Dial Bull. 1987;7:119–29. Gotloib L, Shostak A. Ultrastructural morphology of the peritoneum: new findings and speculations on transfer of solutes and water during peritoneal dialysis. Perit Dial Bull. 1987;7:119–29.
3.
Zurück zum Zitat Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72:171–6.PubMedCrossRef Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72:171–6.PubMedCrossRef
4.
Zurück zum Zitat Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group: morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.PubMed Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group: morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.PubMed
5.
Zurück zum Zitat Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44:729–37.PubMedCrossRef Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44:729–37.PubMedCrossRef
6.
Zurück zum Zitat Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25:S19–29.PubMed Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25:S19–29.PubMed
7.
Zurück zum Zitat Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997;51:182–6.PubMedCrossRef Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997;51:182–6.PubMedCrossRef
8.
9.
Zurück zum Zitat Ohashi K, Hara M, Kawai R, et al. Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int. 1992;41:1646–52.PubMedCrossRef Ohashi K, Hara M, Kawai R, et al. Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int. 1992;41:1646–52.PubMedCrossRef
10.
Zurück zum Zitat Argiles A, Mourad G, Kerr PG, et al. Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant. 1994;9:662–7.PubMed Argiles A, Mourad G, Kerr PG, et al. Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant. 1994;9:662–7.PubMed
11.
Zurück zum Zitat Yokoyama K, Yoshida H, Matsuo N, et al. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol. 2008;69:121–6.PubMedCrossRef Yokoyama K, Yoshida H, Matsuo N, et al. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol. 2008;69:121–6.PubMedCrossRef
13.
Zurück zum Zitat Osada S, Hamada C, Shimaoka T, et al. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant. 2009;24:3504–12.PubMedCrossRef Osada S, Hamada C, Shimaoka T, et al. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant. 2009;24:3504–12.PubMedCrossRef
14.
Zurück zum Zitat Yamaguchi I, Suda H, Tsuzuike N, et al. Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro. Kidney Int. 2003;64:1080–8.PubMedCrossRef Yamaguchi I, Suda H, Tsuzuike N, et al. Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro. Kidney Int. 2003;64:1080–8.PubMedCrossRef
15.
Zurück zum Zitat Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis–medical and surgical treatment. Perit Dial Int. 2009;29 Suppl 2:S211–4.PubMed Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis–medical and surgical treatment. Perit Dial Int. 2009;29 Suppl 2:S211–4.PubMed
16.
Zurück zum Zitat Twardowski ZJ, Nolph kDa, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138–47. Twardowski ZJ, Nolph kDa, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138–47.
17.
Zurück zum Zitat Ikeda K, Higashi T, Sano H, et al. N(epsilon)-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075–83.PubMedCrossRef Ikeda K, Higashi T, Sano H, et al. N(epsilon)-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075–83.PubMedCrossRef
18.
Zurück zum Zitat Solé M, Muñoz-Gómez J, Campistol JM. Role of amyloid in dialysis-related arthropathies. A morphological analysis of 23 cases. Virchows Arch A Pathol Anat Histopathol. 1990;417:523–8.PubMedCrossRef Solé M, Muñoz-Gómez J, Campistol JM. Role of amyloid in dialysis-related arthropathies. A morphological analysis of 23 cases. Virchows Arch A Pathol Anat Histopathol. 1990;417:523–8.PubMedCrossRef
19.
Zurück zum Zitat Shimaoka T, Hamada C, Kaneko K, et al. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant. 2010;10:3379–85.CrossRef Shimaoka T, Hamada C, Kaneko K, et al. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant. 2010;10:3379–85.CrossRef
20.
Zurück zum Zitat Nakamura S, Miyazaki S, Sasaki S, et al. Localization of imidazolone in the peritoneum of CAPD patients: a factor for a loss of ultrafiltration. Am J Kidney Dis. 2001;38:S107–10.PubMedCrossRef Nakamura S, Miyazaki S, Sasaki S, et al. Localization of imidazolone in the peritoneum of CAPD patients: a factor for a loss of ultrafiltration. Am J Kidney Dis. 2001;38:S107–10.PubMedCrossRef
21.
Zurück zum Zitat Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipid oxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int. 2000;58:425–35.PubMedCrossRef Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipid oxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int. 2000;58:425–35.PubMedCrossRef
22.
Zurück zum Zitat Honda K, Hamada C, Nakayama M, Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3:720–8.PubMedCentralPubMedCrossRef Honda K, Hamada C, Nakayama M, Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3:720–8.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Park MS, Lee HA, Chu WS, et al. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int. 2000;20:452–60.PubMed Park MS, Lee HA, Chu WS, et al. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int. 2000;20:452–60.PubMed
24.
Zurück zum Zitat Brownlee M, Vlassara H, Cerami M. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527–37.PubMedCrossRef Brownlee M, Vlassara H, Cerami M. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527–37.PubMedCrossRef
25.
Zurück zum Zitat Bucciarelli LG, Ananthakrishnan R, Hwang YC, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008;57:1941–51.PubMedCentralPubMedCrossRef Bucciarelli LG, Ananthakrishnan R, Hwang YC, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008;57:1941–51.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant. 2006;21:2549–55.PubMedCrossRef De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant. 2006;21:2549–55.PubMedCrossRef
27.
Zurück zum Zitat Lai KN, Lai KB, Lam CW, et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000;35:644–52.PubMedCrossRef Lai KN, Lai KB, Lam CW, et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000;35:644–52.PubMedCrossRef
28.
Zurück zum Zitat Naiki H, Yamamoto S, Hasegawa K, et al. Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils. Amyloid. 2005;12:15–25.PubMedCrossRef Naiki H, Yamamoto S, Hasegawa K, et al. Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils. Amyloid. 2005;12:15–25.PubMedCrossRef
29.
Zurück zum Zitat Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest. 1994;93:521–8.PubMedCentralPubMedCrossRef Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest. 1994;93:521–8.PubMedCentralPubMedCrossRef
Metadaten
Titel
Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients
verfasst von
Hirotaka Nakamoto
Chieko Hamada
Tetsutaro Shimaoka
Yoshimi Sekiguchi
Hiroaki Io
Kayo Kaneko
Satoshi Horikoshi
Yasuhiko Tomino
Publikationsdatum
01.03.2014
Verlag
Springer Japan
Erschienen in
Journal of Artificial Organs / Ausgabe 1/2014
Print ISSN: 1434-7229
Elektronische ISSN: 1619-0904
DOI
https://doi.org/10.1007/s10047-013-0741-1

Weitere Artikel der Ausgabe 1/2014

Journal of Artificial Organs 1/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.